IDO1 and neoplasm: The activation of AhR accelerates the conversion of effector T lymphocytes into regulatory T cells, and then may upregulate IDO1 expression in DC cells, expanding immunoregulatory effects and blocking anti-tumor immune response of the body further [17,18].